BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 26990359)

  • 21. Incidence and characteristics of Epidermal Growth Factor Receptor (EGFR) mutation in non-small-cell lung cancer (Adenocarcinoma histology): A report of 106 patients from Kolkata.
    Chatterjee K; Ray A; Chattopadhyay B
    Indian J Cancer; 2017; 54(1):305-307. PubMed ID: 29199710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas.
    Sun PL; Jin Y; Kim H; Lee CT; Jheon S; Chung JH
    Cancer Cytopathol; 2013 Jun; 121(6):311-9. PubMed ID: 23225576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pyrosequencing analysis of EGFR and KRAS mutations in EUS and EBUS-derived cytologic samples of adenocarcinomas of the lung.
    Stigt JA; 'tHart NA; Knol AJ; Uil SM; Groen HJ
    J Thorac Oncol; 2013 Aug; 8(8):1012-8. PubMed ID: 23807543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of epidermal growth factor receptor mutation in non-small-cell lung carcinoma using cytological and histological specimens.
    Xu H; Sun W; Zhang G; Cheng Y
    J BUON; 2015; 20(1):142-5. PubMed ID: 25778309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study.
    Krawczyk P; Ramlau R; Chorostowska-Wynimko J; Powrózek T; Lewandowska MA; Limon J; Wasąg B; Pankowski J; Kozielski J; Kalinka-Warzocha E; Szczęsna A; Wojas-Krawczyk K; Skroński M; Dziadziuszko R; Jaguś P; Antoszewska E; Szumiło J; Jarosz B; Woźniak A; Jóźwicki W; Dyszkiewicz W; Pasieka-Lis M; Kowalski DM; Krzakowski M; Jassem J; Milanowski J
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):61-8. PubMed ID: 25086987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients.
    Ulivi P; Romagnoli M; Chiadini E; Casoni GL; Capelli L; Gurioli C; Zoli W; Saragoni L; Dubini A; Tesei A; Amadori D; Poletti V
    Int J Oncol; 2012 Jul; 41(1):147-52. PubMed ID: 22504767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.
    Villa C; Cagle PT; Johnson M; Patel JD; Yeldandi AV; Raj R; DeCamp MM; Raparia K
    Arch Pathol Lab Med; 2014 Oct; 138(10):1353-7. PubMed ID: 24571650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases.
    Yang H; Cai L; Zhang Y; Tan H; Deng Q; Zhao M; Xu X
    J Mol Diagn; 2014 Sep; 16(5):558-563. PubMed ID: 24994671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes].
    Zhou CC; Zhou SW; Pan H; Su B; Gao ZQ
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):119-23. PubMed ID: 17645848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides.
    Mitiushkina NV; Iyevleva AG; Poltoratskiy AN; Ivantsov AO; Togo AV; Polyakov IS; Orlov SV; Matsko DE; Novik VI; Imyanitov EN
    Cancer Cytopathol; 2013 Jul; 121(7):370-6. PubMed ID: 23408463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of epidermal growth factor receptor mutations in Jordanian lung adenocarcinoma patients at diagnosis.
    Obeidat N; Awidi A; Ababneh N; Shomaf M; Al-Adaily T; Jaber M; Al-Khateeb M; Abbasi S
    J Cancer Res Ther; 2016; 12(2):616-9. PubMed ID: 27461620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma: Comparing Cobas 4800 EGFR Assay With Sanger Bidirectional Sequencing.
    Ardakani NM; Giardina T; Grieu-Iacopetta F; Tesfai Y; Carrello A; Taylor J; Robinson C; Spagnolo D; Amanuel B
    Clin Lung Cancer; 2016 Sep; 17(5):e113-e119. PubMed ID: 26961433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis.
    Smith GD; Chadwick BE; Willmore-Payne C; Bentz JS
    J Clin Pathol; 2008 Apr; 61(4):487-93. PubMed ID: 17908804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma.
    Paliogiannis P; Attene F; Cossu A; Defraia E; Porcu G; Carta A; Sotgiu MI; Pazzola A; Cordero L; Capelli F; Fadda GM; Ortu S; Sotgiu G; Palomba G; Sini MC; Palmieri G; Colombino M
    Mol Med Rep; 2015 Jul; 12(1):187-91. PubMed ID: 25683726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct sequencing in cytological specimens as a useful strategy for detecting EGFR mutations in non-small cell lung cancer patients.
    Cho MC; Choi CM; Kim S; Jang S; Jang S; Park CJ; Chi HS; Peyton MJ; Lee W; Chun S; Kim SW; Min WK
    Clin Chem Lab Med; 2011 Sep; 50(3):565-72. PubMed ID: 21899495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relationship between EGFR Mutations and Pathological Classification and 
Specimen of Lung Adenocarcinoma].
    Kang L; Zheng J; Zhu X
    Zhongguo Fei Ai Za Zhi; 2017 Jun; 20(6):382-388. PubMed ID: 28641695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
    Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
    Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of EGFR somatic mutations in non-small cell lung cancer (NSCLC) using a novel mutant-enriched liquidchip (MEL) technology.
    Zhang L; Yang H; Zhao Y; Liu W; Wu S; He J; Luo X; Zhu Z; Xu J; Zhou Q; Ren-Heidenreich L
    Curr Drug Metab; 2012 Sep; 13(7):1007-11. PubMed ID: 22591345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
    Malapelle U; Bellevicine C; De Luca C; Salatiello M; De Stefano A; Rocco D; de Rosa N; Vitiello F; Russo S; Pepe F; Iaccarino A; Micheli P; Illiano A; Carlomagno C; Piantedosi FV; Troncone G
    Cancer Cytopathol; 2013 Oct; 121(10):552-60. PubMed ID: 23780873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.